As of December 31, 2024, AIM reported cash, cash equivalents and marketable investments of $4.0 million, compared to $13.1 million as of December 31, 2023. “Our team made significant strides in advancing our development programs along with our collaborators over the course of 2024. As we look ahead, we will continue to execute our corporate and clinical strategies to further establish the foundation upon which we can secure the successful future of AIM and our drug Ampligen for the treatment of major-market unmet medical needs. We are focused on the successful execution of a number of key milestones expected over the course of the next 18 months with the goal of building long-term stockholder value,” commented AIM Chief Executive Officer Thomas Equels
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM announces principal investigator for Ampligen, FluMist clinical study
- AIM ImmunoTech Appoints David Chemerow to Board
- AIM ImmunoTech appoints Chemerow as an Independent Director
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi
- AIM ImmunoTech to not proceed with offering pursuant to registration statement